8-K filing — Jaguar Health, Inc. (JAGX)

Jaguar Health Files S-3 Registration Statement and Provides Clinical Trial Update

Jaguar Health has filed an SEC Form S-3 to register up to $75 million in securities and announced the completion of enrollment for its pivotal crofelemer trial in microvillus inclusion disease (MVID).

Jaguar Health's Napo Pharma Announces Expanded-Access Benefit Of Crofelemer In Congenital Sodium Diarrhea Patient; Plans To File NDA For Crofelemer For MVID In Mid-2027

Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.

Jaguar Health Provides Update On Special Stock Dividend; Nasdaq Sets October 16 Ex-Dividend Date

Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion

Jaguar Health Demonstrates Recap Of Preliminary Data At American College Of Gastroenterology Annual Scientific Meeting For Its Current Trial Of Crofelemer Powder For Oral Solution In Adult Patients With Type 1 Short Bowel Syndrome With Intestinal Failure

Why Option Care Health Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket

Option Care Health jumped 23.8% on reports McKesson and CD&R may acquire it; Freight Technologies led gainers, while NFT Ltd. led decliners.